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ABSTRACT
RNA research and therapy relies primarily on syn-
thetic RNAs. We employed recombinant RNA tech-
nology toward large-scale production of pre-miRNA
agents in bacteria, but found the majority of tar-
get RNAs were not or negligibly expressed. We
thus developed a novel strategy to achieve con-
sistent high-yield biosynthesis of chimeric RNAs
carrying various small RNAs (e.g. miRNAs, siR-
NAs and RNA aptamers), which was based upon
an optimal noncoding RNA scaffold (OnRS) derived
from tRNA fusion pre-miR-34a (tRNA/mir-34a). Multi-
milligrams of chimeric RNAs (e.g. OnRS/miR-124,
OnRS/GFP-siRNA, OnRS/Neg (scrambled RNA) and
OnRS/MGA (malachite green aptamer)) were readily
obtained from 1 l bacterial culture. Deep sequenc-
ing analyses revealed that mature miR-124 and target
GFP-siRNA were selectively released from chimeric
RNAs in human cells. Consequently, OnRS/miR-
124 was active in suppressing miR-124 target gene
expression and controlling cellular processes, and
OnRS/GFP-siRNA was effective in knocking down
GFP mRNA levels and fluorescent intensity in ES-
2/GFP cells and GFP-transgenic mice. Furthermore,
the OnRS/MGA sensor offered a specific strong flu-
orescence upon binding MG, which was utilized as
label-free substrate to accurately determine serum
RNase activities in pancreatic cancer patients. These
results demonstrate that OnRS-based bioengineer-
ing is a common, robust and versatile strategy to
assemble various types of small RNAs for broad ap-
plications.
INTRODUCTION
RNA interference (RNAi) technologies have been widely
utilized for genome function studies. There are also a num-
ber of RNAi-based therapies under clinical trials (1–3)
in addition to an RNA aptamer (Pegaptanib) being ap-
proved by the U.S. Food and Drug Administration for the
treatment of age-related macular degeneration (4). Cur-
rently RNAi agents and noncoding RNA (ncRNA) mate-
rials used for basic, translational and clinical research such
as small interfering RNAs (siRNAs), short hairpin RNAs
(shRNAs), RNA aptamers and microRNAs (miRs or miR-
NAs) are mainly produced through chemical synthesis (5–
9), while other virus and non-virus-vector based strategies
literally utilize DNA agents. Although organic synthesis of
oligonucleotides may be automated, a multi-milligram dose
of 22-nt double-stranded siRNA or miRNA agents for in
vivo testing or projected therapy is very costly. It is also un-
clear to what extent chemical modifications would alter the
structures, biological activities and safety profiles of these
ncRNAs, despite that synthetic ncRNAs exhibit some fa-
vorable pharmacokinetic properties such as a longer half-
life. In vitro transcription (10,11) is another way to produce
RNA agents in variable lengths. However, in vitro transcrip-
tion generally producesRNAmolecules in a test tube onmi-
crograms scale, thus the production of larger quantities of
RNAs requires considerably more of the costly RNA poly-
merases.
With a great interest in developing new strategies to bio-
engineer ready-to-use RNAi agents on a large scale, a suc-
cessful example has been reported very recently for the gen-
eration of fully-processed siRNAs fromp19-expressing bac-
teria (12). On the other hand, tRNA (13–15) and rRNA
(16) have been employed as scaffolds to produce a num-
ber of chimeric RNAs in common strains of bacteria, given
the fact that tRNAs and rRNAs are present as stable RNA
molecules in the cells. The recombinant RNA chimeras
are thus isolated, and the target RNAs may be released in
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demand by corresponding RNase (13,14), ribozyme (15)
or DNAzyme (16) for structural and biophysical analyses.
These recombinant RNA technologies provide a novel way
for a cost-effective and fast production of large quantities of
recombinant RNAs (e.g. milligrams of RNA chimeras from
1 l bacteria culture).
We had taken the initiative to produce pre-miRNA
chimeras (Figure 1a) in common strains of Escherichia
coli using tRNA scaffold (17). We hypothesized that fu-
sion tRNA/pre-miRNA isolated from bacteria might act
as a ‘prodrug’ where pre-miRNA could be selectively pro-
cessed to mature miRNA in human cells, and the tRNA
scaffold would be degraded to tRNA fragments (tRFs). In
the present study, we demonstrated that the majority of
tRNA/pre-miRNA chimeras did not accumulate in bacte-
ria or only at a negligible level, thus we developed a novel
optimal ncRNA scaffold (OnRS)-based strategy to achieve
a consistent high-yield production of chimeric RNAs in E.
coli that offers the versatility to carry various types of func-
tional small RNAs of interests such as miRNAs, siRNAs
and RNA aptamers (Figure 1b). This approach is proven
robust and shall have broad applications to engineering of
target chimeric RNAi agents and RNA sensors that may be
utilized as research tools and further developed as therapeu-
tic agents and/or diagnostic tools.
MATERIALS AND METHODS
Bacterial culture
All E. coli stains were cultured at 37◦C in LB broth sup-
plemented with 100 g/ml ampicillin. DH5 (Life Tech-
nologies, Grand Island, NY,USA) was used for cloning and
HST08 (Clontech Laboratories,Mountain View, CA,USA)
was employed for the production of multi-milligrams of
chimeric RNAs. Other strains such as DH5, Top 10 (Life
Technologies, Grand Island, NY, USA) and BL21 (Sigma–
Aldrich, St. Louis, MO, USA) were also used to evaluate
ncRNA expression/accumulation.
Human cell culture
The human carcinoma cell line A549 was purchased from
American Type Culture Collection (Manassas, VA, USA),
and ES-2/GFP was from Cell Biolabs (San Diego, CA,
USA). Both cell lines were maintained in Roswell Park
Memorial Institute (RPMI) 1640 Medium with 10% fetal
bovine serum at 37◦C in a humidified atmosphere with 5%
CO2 and 95% air.
Prediction of RNA secondary structures
The secondary structures of chimeric ncRNAs were
predicted using the CentroidFold (http://www.ncrna.org/
centroidfold) (18) and CentroidHomfold (http://www.
ncrna.org/centroidhomfold) (19).
Construction of plasmids
Individual tRNA/pre-miRNA expression plasmids were
cloned as we reported (17), following PCR amplification
of target sequences from human genomic DNA using gene
specific primers (IDT, San Diego, CA, USA) (Supplemen-
tary Table S1). To create OnRS/miR-124, OnRS/Neg,
OnRS/GFP-siRNA and tRNA-miR-155/GFP-siRNA ex-
pression plasmids, the oligonucleotides (Supplementary Ta-
ble S1) were annealed and amplified, then the amplicons
were cloned into the vector pBSMrnaSeph (14) (kindly pro-
vided byDr Luc Ponchon, France) linearized by endonucle-
ases SalI-HF R© and AatII (New England Biolabs, Ipswich,
MA). To construct OnRS/MGA5 and OnRS/MGA3 ex-
pression plasmids, tRNA/mir-34a was used as a template
for the amplification of target sequences using the oligonu-
cleotides (Supplementary Table S1), and then the ampli-
cons were inserted into pBSMrnaSeph vector linearized by
SacII and EagI (New England Biolabs) which removed the
sephadex aptamer from tRNA scaffold at the same time.
All inserts were confirmed by Sanger sequencing analyses
at UC Davis Genome Center.
Expression of chimeric RNAs in E. coli
Chimeric RNAs were expressed in HST08 on a large scale
as described (13,14,17). Total RNAs were isolated from
E. coli using the Tris–HCl-saturated phenol extraction
method, quantitated with a NanoDrop 2000 spectropho-
tometer (ThermoFisher Scientific, Rockford, IL,USA) and
analyzed by denaturing urea (8 M) polyacrylamide (8%)
gel electrophoresis (PAGE). All images were acquired with
ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA,
USA). Intensities of bands were used to provide a rough es-
timation of relative levels of recombinant ncRNAs present
in the total RNAs.
Purification of recombinant ncRNAs
Purification of recombinant ncRNAs was conducted with a
NGC QUEST 10PLUS CHROM fast protein liquid chro-
matography (FPLC) System (Bio-Rad). Separation of re-
combinant ncRNAs from total RNAs was achieved on a
UNO Q6 anion-exchange column (Bio-Rad), which was
first equilibrated with Buffer A (10 mM sodium phosphate,
pH 7.0) at a flow rate 5.0 ml/min for 0.5 min, followed by
a gradient elution at the same flow rate, 0–56% Buffer B
(Buffer A + 1M sodium chloride) in 0.5 min, 56% Buffer B
for 2min, 56–65%Buffer B in 10min, and then 100%Buffer
B for 2 min, 100–0% Buffer B in 0.5 min and 100% Buffer
A for 5 min. FPLC traces were monitored at 260 nm using
a UV/Vis detector. Peak areas were employed to estimate
the relative levels of recombinant ncRNAs within the total
RNAs, which agrees with those determined by urea–PAGE
analyses. After analyzed on a denaturing PAGE gel, the
fractions containing pure ncRNAs were pooled. Recombi-
nant ncRNAs were precipitated with ethanol, reconstituted
with nuclease-free water, and then desalted and concen-
trated with Amicon ultra-2 ml centrifugal filters (30 kDa;
EMD Millipore, Billerica, MA, USA). The only exception
was OnRS/MGA that was reconstituted with 10 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
(pH 7.4) buffer. The quantity of purified ncRNAs was de-
termined using NanoDrop and the quality was validated by
PAGE analysis before other experiments.
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Figure 1. High-yield production of recombinant miRNA/siRNA agents in E. coli using OnRS-based technology. (a) Urea–PAGE analysis of total RNAs
showed that there was large variability in the expression of chimeric pre-miRNAs in E. coli using the same tRNA scaffold. Total RNAs isolated from
untransformed HST08 (WT) E. coli were used as a control. The heat color gradation indicates the base-pairing probability from 0 to 1. (b) The chimeric
tRNA/mir-34a robustly expressed inE. coliwas developed as anOnRS that offered a consistent high-level expression of chimericmiRNAs (e.g. OnRS/miR-
124) and siRNAs (e.g. OnRS/GFP-siRNA) in E. coli (e.g.∼15–20% of total RNAs). In contrast, there was no or minimal expression of miR-124 and GFP
siRNA using the tRNA and tRNA/mir-155 scaffold, respectively. (c and d) Representative FPLC traces during the purification of OnRS/miR-124 and
OnRS/GFP-siRNA, respectively. Inserts are corresponding urea–PAGE analyses of collected fractions (1, 2, 3 and 4) eluted at 8.3 and 8.7 min, respectively,
which confirmed the purity of isolated recombinant ncRNAs.
Deep sequencing of small RNAs and data analysis
A549 cells were transfected with 50 nM FPLC-purified
OnRS/miR-124 and tRNA/mir-34a (OnRS) and ES-
2/GFP cells were transfected with OnRS/Neg and
OnRS/GFP-siRNA using Lipofectamine 2000 (Life Tech-
nologies). Total RNAs were isolated using a Direct-zol
RNA extraction kit (Zymo Research, Irvine, CA) at 48 h
post-transfection, and small RNA libraries were generated
using the Illumina TruseqTM Small RNA Preparation
kit (Illumina, San Diego, CA, USA) according to the
instructions. The purified cDNA library was used for
cluster generation on Illumina’s Cluster Station and then
sequenced on Illumina GAIIx following vendor’s instruc-
tions. Raw sequencing reads (40 nt) were obtained using
Illumina’s Sequencing Control Studio software version 2.8
(SCS v2.8) following real-time sequencing image analysis
and base-calling by Illumina’s Real-Time Analysis version
1.8.70 (RTA v1.8.70). The extracted sequencing reads were
used for the standard sequencing data analysis by following
a proprietary pipeline script, ACGT101-miR v4.2 (LC
Sciences, Houston, TX, USA) (20,21). Cells were treated in
triplicate and sequenced separately.
Reverse transcription quantitative real-time PCR (RT-
qPCR)
Cells were transfected with various doses of recombinant
ncRNAs and harvested at particular time points. Total
RNAs were isolated using Direct-zol RNA isolation kit
(Zymo Research), and RNA concentrations were deter-
mined using NanoDrop 2000 spectrophotometer. RT was
conducted with NxGen M-MuLV reverse transcriptase
(Lucigen, Middleton, WI, USA), and qPCR analysis was
carried out on a CFX96 Touch real-time PCR system (Bio-
Rad) using quantitative RT-PCR Master mix (New Eng-
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land Biolabs), as described (17,22). Levels of miRNAs were
normalized to U74, and mRNA levels were normalized to
PPIA. Gene specific primers were shown in Supplementary
Table S1. Each experiment was conducted in triplicate and
each sample was measured 2–3 times. Similar results were
obtained when the study was repeated.
Western blots
A549 cells were transfected with 100 nM OnRS/miR-124
or OnRS/Neg and harvested after 48 h. Cell lysates were
prepared with Radioimmunoprecipitation assay (RIPA) ly-
sis buffer (Rockland Immunochemical Inc., Limerick, PA,
USA) consisting of complete protease inhibitor cocktail
(Roche, Nutley, NJ, USA). Protein concentrations were de-
termined using the BCA Protein Assay Kit (Thermo Fisher
Scientific). Whole-cell proteins (40 g per lane) were sepa-
rated on 10% SDS-PAGE gel, and electrophoretically trans-
ferred onto polyvinylidene fluoride (PVDF) membranes
(Bio-Rad). Membranes were then incubated with selec-
tive antibody against P-STAT-3, STAT-3 (Cell Signaling
Technology, Danvers, MA, USA) or GAPDH (Santa Cruz
Biotech Inc., Texas, TX, USA) and subsequently with per-
oxidase anti-rabbit (Jackson ImmunoResearch Inc., West
Grove, PA, USA) or anti-mouse IgG (Cell Signaling). The
membranes were then incubated with ECL substrates (Bio-
Rad), and images were acquired with ChemiDocMP Imag-
ing System (Bio-Rad). Cells were treated in triplicate and
the same results were obtained when the whole study was
repeated.
Apoptosis assay
The apoptosis assay was performed by using a FACS An-
nexin V assay kit (Trevigen, Inc., Gaithersburg, MD, USA)
following the manufacturer`s protocol. Briefly, A549 cells
were transfected with 100 nM recombinant ncRNAs, har-
vested at 72 h post-transfection, incubated with Annexin V-
FITC conjugate and propidium iodide solution, and then
the samples were analyzed on a FACScan flow cytometer
(BD Biosciences, San Jose, CA, USA). Data analysis was
performed using Flowjo (Ashland, OR, USA). Cells were
treated in triplicate and similar results were obtained when
the whole experiment was repeated.
MTT assay
A549 cells were transfected with 20 or 100 nM chimeric
RNAs. At 72 h post-transfection, cell viability was deter-
mined using MTT as we described previously (23). Cells
were treated in triplicate and similar results were obtained
when the whole study was repeated.
Real-time cell growth analysis
A549 cells were seeded 40,000/well on an 8-well E-Plate and
treated with 20 or 100 nM recombinant ncRNA 24 h later.
Cell growth was monitored using an iCELLigence system
(ACEA Biosciences, San Diego, CA, USA). Similar results
were obtained when the whole experiment was repeated for
three times.
In vitro knockdown of GFP
ES-2/GFP cells were seeded 8000 cells/well on a 24-well
plate and transfected with 5 or 15 nM FPLC-purified
chimeric RNAs at 24 h later. The fluorescence was moni-
tored with an Olympus IX81 microscope (Olympus, Center
Valley, PA, USA) at 24, 48 and 72 h post-transfection. All
images were acquired using the same settings at the same
time. At the end of the study, total RNAs were isolated
from the cells and subject to RT-qPCR evaluation of GFP
mRNA and siRNA levels. Cells were treated in triplicate,
and similar results were obtained when the whole experi-
ment was repeated.
In vivo knockdown of GFP
All animal procedures were approved by the Institutional
Animal Care and Use Committee at UC Davis. Six- to
seven-week-old male GFP-transgenic (C57BL/6-Tg(CAG-
EGFP)1Osb/J) mice (24) (The Jackson Laboratory, Bar
Harbor, ME, USA) were injected i.v. with 75 g FPLC-
purifiedOnRS/Neg (N= 3) or OnRS/GFP-siRNA (N= 4)
after formulated with in vivo-jetPEI (Polyplus-transfection
Inc., New York, NY, USA) each day for consecutive 3
days. Three days after the last injection, mice were sacri-
ficed and liver tissues were collected. Frozen sections (8m)
were prepared after embedded inTissue-TekO.C.T. (Sakura
Finetek, Torrance, CA, USA) and examined directly using
a Zeiss Axio Observer.z1 Microscope coupled to a Zeiss
LSM 710 Scanning Device (Zeiss, Oberkochen, Germany).
Different batches of sections (8 m) were fixed with 4%
paraformaldehyde (Sigma–Aldrich, St. Louis, MO, USA)
and stained with 1 g/ml 4′,6-diamidino-2-phenylindole
(DAPI; Sigma–Aldrich). GFP fluorescence and DAPI-
stained nuclei images were recorded with confocal micro-
scope sequentially and then merged together.
In addition, liver tissues were subject to RNA isolation
and RT-qPCR analyses for GFP mRNA and siRNA levels
against 18S andU74 was used as control, respectively. Gene
specific primers were presented in Supplementary Table S1.
Malachite green (MG) aptamer binding assays
Absorbance scanning was performed from 550 to 700 nm
using a SpectraMax Microplate Reader (Molecular De-
vices, Sunnyvale, CA, USA) after 32 g purified ncRNAs
or 80 g total RNAs were incubated with 10 M MG in
100 mM KCl, 5 mM MgCl2 and 10 mM HEPES (pH 7.4)
buffer in a total volume of 100 l. Fluorescent intensity was
determined at 630/650 nm (excitation/emission) with the
same SpectraMax Microplate Reader for purified ncRNAs
(32 g) or total RNAs (80 g) in the absence and presence
of MG (10 M). To establish the linearity of MGA-bound
MG fluorescent intensity vis-a`-vis MG and MGA concen-
trations, the intensities of fluorescence were examined when
2.08 MOnRS/MGA5 was exposed to 0–10 MMG and
10 M was incubated with 0–5.2 M OnRS/MGA5, re-
spectively, in 10 mM HEPES (pH 7.4) buffer in a total vol-
ume of 100 l. Each assay was carried out in triplicate, and
all experiments were repeated at least once that showed sim-
ilar results.
Nucleic Acids Research, 2015, Vol. 43, No. 7 3861
Serum RNase activity assay
Serum specimens from IRB-approved, prospectively-
collected UC Davis Pancreas Registry bank were utilized.
The serum has been processed uniformly within 4 h of
blood collection, aliquoted and stored in a −80◦C freezer
till usage with minimal freeze-thaw cycle. A total of 20
patients’ serum from 10 pancreatic ductal adenocarcinoma
(PDAC) (5 early-stage PDAC (American Joint Committee
of Cancer, Stages 1 & 2)) and 10 benign/normal pancreas
cases (five chronic pancreatitis and five normal pancreases)
were selected. The PDAC cases consisted of four males and
six females, benign/normal of five males and five females.
Age ranges were 51–80 (mean = 67 years old) in the
PDAC and 37–85 (mean = 60 years old) in benign/normal
groups. The selected serums were from a period spanning
March 2012 to September 2014. A normal pooled human
serum sample (Fisher Scientific Inc., Waltham,MA, USA),
human recombinant RNase A (Novoprotein, Summit,
NJ, USA) and human recombinant angiogenin (R&D
Systems, Minneapolis, MN, USA) were used for method
development.
To evaluate the change in MGA-bound MG fluorescent
intensity in relationship to incubation time (0–30 min) af-
ter exposure to human serum, 2.08 MOnRS/MGA5 was
incubated with 0.4 or 2.0 l normal pooled human serum
in 10 mM HEPES (pH 7.4) buffer in a total volume of
90 l, and then fluorescence was determined after the ad-
dition of 10 l MG to a final 10 M concentration. To
assess the protection of MGA by in vivo-jetPEI, 2.08 M
OnRS/MGA5 and 1.0 l pool human serum were incu-
bated for 0–60 min. To determine the dose response, var-
ious volumes of the pooled human serum (0.01–10 l) or
concentrations of recombinant human RNase A (0–10−4
g/l) and angiogenin (0–10−2 g/l) were incubated with
2.08 MOnRS/MGA5 for 10 min. To define the influence
of RNase inhibitor, the pooled human serum (0, 1, 2 and
5 l) was incubated with 2.08 M OnRS/MGA5 for 10
min, with or without 0.4 U/l RNase inhibitor (Lucigen,
Middleton, WI, USA). Each incubation reaction was car-
ried out in triplicate, and all experiments were repeated at
least once that offered consistent findings.
Based upon the linearity of fluorescent intensity overMG
and MGA concentrations, incubation time and quantity of
human sera, 0.4 l patient serum sample was incubated
with 2.08 M OnRS/MGA5 in 10 mM HEPES (pH 7.4)
buffer in a total volume of 90 l at 37◦C for 5 min and
then 10 l MG was added to give 10 M final concentra-
tion for the determination of fluorescence at 630/650 nm
(excitation/emission). SerumRNase activity was calculated
as the change in fluorescent intensity over time and quan-
tity of serum sample, i.e., A.U./min/l. Each patient sam-
ple was assayed twice with <10% variations.
Statistical analysis
Values were expressed as mean ± SD. According to the
number of groups and variances, data were analyzed with
unpaired Student’s t-test, or one-way or two-way ANOVA
(GraphPad Prism, San Diego, CA, USA). Difference was
considered as significant for P-value less than 0.05 (P <
0.05).
RESULTS
An OnRS is developed to achieve high-yield production of re-
combinant RNAi agents
Motivated by the concept of ‘prodrug’ and the idea
to deploy biological RNAs to perform RNA actions,
we intended to bioengineer tRNA fusion pre-miRNA
(tRNA/mir) agents in common strains of bacteria (Fig-
ure 1a) on a large scale, i.e. milligrams of recombinant ncR-
NAs from 1 l bacterial culture. Thus, a series of plasmids
were created and employed to transform E. coli. Surpris-
ingly, we found that the levels of recombinant pre-miRNA
chimeras expressed/accumulated in HST08 E. coli were
largely variable when the same tRNA scaffold was used.
Themajority of tRNA/pre-miRNAchimeras were unfortu-
nately not accumulated or at a negligible level (Figure 1a).
Use of other E. coli strains still offered no or even lower
levels of target ncRNA chimeras (data not shown). Nev-
ertheless, given the findings that tRNA/mir-34a was accu-
mulated to a high level in bacteria (e.g. ∼15–20% of to-
tal RNAs) and chimeric tRNA/mir-34a was stable and se-
lectively processed to mature hsa-miR-34a in various types
of human carcinoma cells (unpublished data), we hypothe-
sized that tRNA/mir-34a might be developed as an OnRS
over the tRNA scaffold towards a consistent high-level pro-
duction of target miRNAs (Figure 1b).
We thus took up the challenge to assemblemiR-124 using
the OnRS (tRNA/mir-34a) platform, noticing that miR-
124 differs much frommiR-34a in size (20 versus 22 nt) and
arm of origin (3′ versus 5′). We replaced the 22-nt miR-34a-
5p with 20-nt miR-124-3p and substituted their comple-
mentary sequences accordingly (Supplementary Table S1),
which indeed offered a high-level expression of OnRS/miR-
124 chimera in HST08 E. coli (Figure 1b). Recombinant
OnRS/miR-124 was then readily purified to a high degree
of homogeneity (>99%) using the anion-exchange FPLC
method (Figure 1c). Likewise, the OnRS was able to as-
semble other miRNAs (e.g. 21-nt miR-27b and 22-nt miR-
22, etc.; unpublished data) and a 22-nt scrambled RNA se-
quence (chimeric RNA was named OnRS/Neg and used
as a control in the following studies; Supplementary Ta-
ble S1), which were all consistently produced in HST08
E. coli at high yields and on a large scale, i.e. >15% of
OnRS/miRNAs in total RNAs and >1.5 mg of FPLC-
purified OnRS/miRNAs from 0.5 l bacterial culture at all
times.
We further evaluated if we could utilize this OnRS-
based approach to producemilligrams of functional siRNA
agents in 1 l E. coli culture. A 22-nt GFP siRNA (25)
was chosen as a model siRNA to assemble chimeric
OnRS/GFP-siRNA (Supplementary Table S1). In con-
trast to a minimal level of accumulation in bacteria when
tRNA/mir-155 was utilized as a carrier, the use of OnRS
(tRNA/mir-34a) provided a consistent high-level expres-
sion of OnRS/GFP-siRNA (Figure 1b) and facilitated the
FPLC purification of recombinant ncRNAs (Figure 1d). As
a result, we were able to produce 1.5–2.0 mg, >98% pure
OnRS/GFP-siRNA from 0.5 l bacterial culture every time.
These results indicate that target miRNA/siRNA agents
can be assembled by using OnRS-based platform to offer
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a consistent high-level production of chimeric ncRNAs in
bacteria.
Target miRNAs/siRNAs are selectively released from
chimeric ncRNAs in human cells while tRNA scaffold is pro-
cessed to tRNA fragments (tRFs)
Next we assessed if mature miR-124 could be selectively
produced from OnRS/miR-124 in human cells. An unbi-
ased deep sequencing study was conducted after the prepa-
ration of small RNAs library from human lung carci-
nomaA549 cells at 48 h post-transfection with OnRS/miR-
124 and OnRS (tRNA/mir-34a). The data showed that
OnRS/miR-124 was selectively processed to large num-
bers (5613 ± 975 reads) of 20-nt miR-124 in A549 cells
(Figure 2a). In contrast, there was 0 ± 1 reads of mature
miR-124 identified in A549 cells treated with tRNA/mir-
34a (OnRS) that actually offered 22-nt miR-34a. Other
miR-124 isoforms including those of 21 nt in length, as
well as some passenger strands, were also noted whereas
at much lower levels (Supplementary Table S2). In addi-
tion, OnRS/miR-124 had no or relatively much smaller in-
fluence on other cellular miRNAs including the hsa-mir-
34a-p3 fragment (Figure 2a and Supplementary Table S3),
while the tRNA scaffold was degraded to tRFs that actually
exhibited similar patterns between OnRS/miR-124- and
tRNA/mir-34a-treated cells (Figure 2c and Supplementary
Table S2).
Likewise, we conducted the unbiased deep sequencing
analyses of cellular small RNAs in human ES-2/GFP cells
at 48 h post-transfection with FPLC-purified OnRS/GFP-
siRNAandOnRS/Neg. The data showed thatGFP-siRNA
levels were about 1000-fold higher in ES-2/GFP cells
treated with chimeric OnRS/GFP-siRNA than the control
OnRS/Neg (Figure 2b), which was mainly attributable to
the increase in 22-, 23- and 21-nt isoforms and accompa-
nied by lower levels of passenger strands (Supplementary
Table S4). It was also noted that OnRS/Neg was indeed
processed to a number of scrambled RNAs at 22–23 nt in
length, but at much lower levels (Supplementary Table S4),
which might be related to a lower stability of the scrambled
RNAs or insufficient processing. Nevertheless, there were
no orminimal differences in the levels of other cellularmiR-
NAs betweenOnRS/GFP-siRNA- andOnRS/Neg-treated
cells (Supplementary Table S5). Furthermore, the tRF pat-
terns were also similar between OnRS/GFP-siRNA and
OnRS/Neg-treated cells (Figure 2d and Supplementary Ta-
ble S4), despite that overall tRF levels were much lower in
ES-2/GFP cells than A549 cells. Together, these results sup-
port the utility of OnRS for ‘stealth delivery’ of target miR-
NAs and siRNAs into human cells beyond high-yield pro-
duction of the chimeric ncRNAs in bacteria and the use of
OnRS/Neg as a control to assess OnRS/siRNA activities.
OnRS-carried miR-124 is biologically/pharmacologically
active in controlling target gene expression and cancer cel-
lular processes
Then we evaluated the bioactivities of OnRS-carried miR-
124, as miR-124 is known to regulate a number of tar-
get genes such as the oncogenic signal transducer and
activator of transcription 3 (STAT3), enhance apoptosis,
and inhibit cell proliferation (26–28). Consistent with deep
sequencing data, selective stem–loop RT-qPCR analyses
showed that mature miR-124 levels were around 1000-fold
higher in A549 cells from day 1 to 4 after transfection with
OnRS/miR-124, compared with OnRS/Neg (Figure 3a).
Increase in miR-124 in OnRS/miR-124-treated A549 cells
led to a 60% reduction of STAT3 protein levels (Figure
3b), and 1- to 2-fold greater degrees of early and late
apoptosis as well as necrosis (Figure 3c). Consequently,
OnRS/miR-124 exhibited significantly greater antiprolifer-
ative activity than OnRS/Neg, as demonstrated by MTT
assay and using a Real-Time Cell Analyzer (Figure 3d-e).
These results demonstrate that chimeric OnRS/miR-124 is
biologically/pharmacological active in regulating miR-124
target gene expression and controlling cancer cell growth
after being processed to mature miR-124 in the cells.
OnRS-carried GFP siRNA is effective in knocking down
GFP expression in vitro and in vivo
We also assessed the effectiveness of OnRS-carried
GFP siRNA using GFP-expressing ES-2 cells and GFP-
transgenic mouse models. In ES-2/GFP cells, OnRS/GFP-
siRNA significantly suppressed the GFP fluorescence
intensity and mRNA levels at 72 h post-transfection
(Figure 4a and b), which was associated with 3 orders
of magnitude increase in GFP siRNA levels (Figure 4c).
We then treated GFP-transgenic mice (24) with in vivo-
jetPEI-formulated OnRS/GFP-siRNA. Compared to the
GFP-transgenic mice treated with the same doses of in
vivo-jetPEI-formulated OnRS/Neg, there was a remarkable
reduction of hepatic GFP fluorescence intensity (Figure 4d
and e) and mRNA levels (Figure 4f) in GFP-transgenic
mice treated with OnRS/GFP-siRNA, which was linked
to an over 3000-fold increase in GFP siRNA levels. These
data indicate that chimeric GFP-siRNAs produced on
large scale using the OnRS cargo are effective agents for in
vitro and in vivo RNAi applications.
Utility of OnRS for high-level production of active RNA ap-
tamer chimeras in bacteria
Encouraged by these findings, we further challenged the
potential applications of OnRS to the production of func-
tional RNA aptamers. A malachite green aptamer (MGA)
(9) was chosen as amodel aptamer and inserted at the 5′ and
3′ of miR-34a to offer OnRS/MGA5 and OnRS/MGA3,
respectively (Figure 5a). Both chimeras were revealed to be
expressed at surprisingly high levels in bacteria, i.e. over
50% of OnRS/MGA in total RNAs (Figure 5b). Thus,
we could use FPLC (Figure 5c) to easily purify 5–6 mg
OnRS/MGA from 15 to 20 mg total RNAs isolated from
0.5 l bacterial culture at all times.
Consistent with the reported property of MGA (9), we
found that the wavelength of MG maximum absorbance
was shifted from 618 to 630 nm upon binding the label-free,
chimeric OnRS/MGA sensor (Figure 5d). Interestingly, the
use of FPLC-purified OnRS/MGA or total RNAs isolated
from OnRS/MGA-expressing bacteria gave the same shift
in wavelength, whereas a sephadex aptamer (OnRS/Seph)
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Figure 2. Fate of recombinant ncRNAs in human cells. (a and b) Unbiased deep sequencing study revealed that OnRS-carried miR-124 and GFP-siRNA
were precisely processed to target small RNAs, leading to 3 orders of magnitude increase in miR-124 in A549 cells and GFP siRNA in ES-2/GFP cells,
respectively. Note the presence of miRNA and siRNA isoforms as well as corresponding passenger strands and other small RNAs at much lower levels
(Supplementary Tables S2 and S4). In contrast, the levels of other cellular miRNAs showed no or minor changes (Supplementary Tables S3 and S5).
Values are mean ± SD of triplicated treatments that were sequenced separately. (c and d) Mapping major cellular tRFs derived from OnRS/miR-124
versus OnRS (tRNA/mir-34a) in A549 cells and OnRS/GFP-siRNA versus OnRS/Neg in ES-2/GFP cells, respectively. Shown are the mean numbers of
reads of triplicated treatments. 3000 and 1000 reads was used as a cut off for the A549 and ES-2/GFP cells, respectively. See the Supplementary Tables S2
and S4 for a complete list of tRFs derived from each ncRNA.
and corresponding total RNAs did not, indicating the
selectivity of MGA–MG interactions. The function of
OnRS-carried MGA was further demonstrated by a strong
fluorescent intensity at 630/650 nm (excitation/emission)
upon binding MG (Figure 5e). In contrast, label-free
OnRS/MGA itself did not exhibit any fluorescence, and
only minimal basal-level MG fluorescent intensity was
shown in the absence or presence of non-MGA-containing
total RNAs and HPLC-purified OnRS/Seph (Figure 5e),
supporting the specificity of MGA-bound-MG fluores-
cence. These results demonstrate that OnRS is also power-
ful for high-yield production of functional RNA aptamers
of interests.
Application of label-free, OnRS-carried malachite green ap-
tamer sensor to determine serum RNase activities among hu-
man pancreatic cancer patients
Given the unique property of MGA-bound MG in exhibit-
ing the fluorescence, we further developed anOnRS/MGA-
based RNase activity assay and employed the label-free
chimeric OnRS/MGA to investigate and compare serum
RNase activities between human PDAC and benign (in-
cluding chronic pancreatitis)/normal patients because pan-
creatic cancer patients were shown to have much higher
serum RNase activities (29). The intensity of the fluo-
rescence increased with MG concentrations and nearly
plateaued at 10 MMGwhen OnRS/MGA concentration
was fixed at 2.08 M (or 0.16 g/l), while a good linear
range was shown for 0.04–5.2 MOnRS/MGA when MG
concentration was fixed at 10 M (Figure 6a). As expected,
3864 Nucleic Acids Research, 2015, Vol. 43, No. 7
e
0
1
2
3
4 OnRS/Neg
OnRS/miR-124
*
* *
Late
Apoptosis
Early
Apoptosis
Neucrosis
Fo
ld
 o
f c
ha
ng
e
OnRS/Neg             OnRS/miR-124
P
ro
pi
di
um
 Io
di
de
Annexin V-FITC
104
103
102
101
100
Q2
5.29
Q1
2.06
Q4
90.5
Q3
2.41
100 102 104
Annexin V-FITC
100 102 104
Q2
15.5
Q1
4.00
Q4
75.3
Q3
5.71
20 nM 100 nM
0.0
0.5
1.0
1.5 OnRS/Neg
OnRS/miR-124
* *
C
e
ll 
V
ia
b
ili
ty
 (
F
o
ld
)
a
c
b
1 2 3 4
10-1
100
101
102
103
104
OnRS/Neg
OnRS/miR-124
Days after transfection
m
iR
-1
24
ex
pr
es
si
on
 (f
ol
d)
0
2
4
6
8
10
0 20 40 60 80 100
OnRS/Neg
OnRS/miR-124
0
2
4
6
8
10
0 20 40 60 80 100
OnRS/Neg
OnRS/miR-124
C
el
l i
nd
ex
Time (h) Time (h)
20 nM 100 nMd
STAT3
p-STAT3
GAPDH
OnRS/miR-124 OnRS/Neg 
Figure 3. OnRS-carried miRNA is biologically/pharmacologically active in regulating target gene expression and controlling cellular processes in human
cells. (a) RT-qPCR analysis revealed that mature miR-124 levels retained 3 orders of magnitude higher in A549 cells for 4 days since transfection with
OnRS/miR-124, as compared with OnRS/Neg. (b) Western blots showed that OnRS/miR-124 was effective in reducing the protein expression level of
miR-124 target gene STAT3 in A549 cells at 72 h post-transfection. (c) Flow cytometric analyses demonstrated that OnRS/miR-124 was effective in
inducing apoptosis in A549 cells at 48 h post-transfection. Cells treated with OnRS/Neg were used as controls. (d) MTT assay showed that OnRS/miR-
124 significantly suppressed the proliferation of A549 cells at 72 h post-treatment, as compared to OnRS/Neg. (e) Inhibition of A549 cell proliferation by
OnRS/miR-124 was also demonstrated when cell growth was monitored using Icelligence Real-Time Cell analyzer. The arrow points to the time point of
ncRNA treatment. Values are mean ± SD of triplicated treatments. *P < 0.01.
the intensity of OnRS/MGA-bound MG fluorescence was
decreased over time (Figure 6b) when OnRS-carried MGA
was cleaved by the RNases in a normal pooled human
serum sample, and the response was dependent upon the
doses of human sera (Figure 6c) while sera themselves did
not have any significant fluorescence. Indeed, use of in vivo-
jetPEI provided good protection against the decrease in
fluorescent intensity over time, and addition of RNase in-
hibitor completely blocked the cleavage of OnRS/MGA by
serum RNases. These data indicate that OnRS/MGA may
be utilized to directly determine RNase activities.
To define the role of RNase A (the major form RNase in
human serum) in the cleavage of chimeric ncRNAs, we di-
rectly compared the susceptibility of OnRS-carried MGA
to cDNA-expressed RNase A and angiogenin (RNase 5).
As manifested by the degrees of change in the intensity
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of MGA-bound MG fluorescence, 2.08 M OnRS/MGA
was completely cleaved by 5.0 × 10−5 g/l RNase A in
10 min, whereas only 40% OnRS/MGA was degraded by
500-fold higher concentration (0.01 g/l) of angiogenin
in 30 min. Since RNase A is the major form of RNase
in human serum (30), this assay would mainly indicate
pancreas-derived RNase A activity in human serum. There-
fore, we utilized OnRS/MGA to evaluate the RNase activ-
ities in a set of serum samples prospectively collected from
PDAC and benign/normal patients. The data showed that
serumRNase activities (A.U./min/l) were significantly (P
< 0.01) higher in PDAC (196 ± 22) than benign/normal
(118 ± 8) patients. These results implicate that chimeric
MGA sensor produced using the OnRS platform could be
useful for determination of RNase activities.
DISCUSSION
A general approach has been established for a consistent,
cost-effective production of multiple to tens of milligrams
of chimeric ncRNAs in 1 l culture of a common strain of
E. coli, bearing various types of small RNAs of interests.
The OnRS used in this platform is based upon the tRNA
fusion pre-miRNA-34a that is resistant to nucleolytic di-
gestion in bacteria and thus accumulated to significantly
high level (e.g. >15% of total RNAs) for an easy purifi-
cation with the anion-exchange FPLC method. The miR-
34a-5p/miR-34a-3p duplex within the OnRS cargo may
be replaced by any target double-stranded small RNAs
such as siRNA or miRNA/miRNA* duplex (Figure 1b) to
achieving high-yield production of corresponding chimeric
siRNA or miRNA agents, as exemplified by successful
production of >1.5 mg of OnRS/miR-124, OnRS/GFP-
siRNA and control OnRS/Neg chimeras from 0.5 l bacte-
rial culture in this report. In addition, single-stranded small
RNAs such as RNA aptamers can be sprouting at partic-
ular sites on OnRS to offer the aptamer chimeras (Fig-
ure 5a), which are nicely demonstrated by the assembling of
OnRS/MGA5 and OnRS/MGA3 sensors. The robustness
and versatility of OnRS-based platform is also supported
by successful production of other target RNA agents (e.g.
miR-27b, miR-22 and a vascular endothelial growth factor
(VEGF) aptamer, etc.; unpublished data), whereas its appli-
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cation to bioengineer other types of biological RNAs such
as catalytic RNAs (ribozymes) for biotransformation and
guide RNAs (gRNAs) for genome editing warrants further
investigations.
Chimeric OnRS/miRNAs and OnRS/siRNAs are ex-
pected to act as ‘pro-drugs’ for the ‘delivery’ of target RNAi
agents into the cells. Indeed they were selectively processed
to large numbers of target miRNAs and siRNAs in hu-
man cells, as determined by unbiased deep sequencing stud-
ies (Figure 2a and b). So was the scrambled RNA from
OnRS/Neg (Supplementary Table S4). The presence of
small RNA isoforms differing in 1- or 2-nt at 5′ or 3′ within
chimeric ncRNA- and vehicle-treated human cells (Sup-
plementary Tables S2 and S4) may indicate the flexibilities
of endoribonucleases in producing small RNAs from pre-
miRNAs or shRNAs (31–33). As a result, selective stem-
loop RT-qPCR assays revealed a three orders of magnitude
increase in miR-124 in A549 cells and GFP siRNA in ES-
2/GFP cells, respectively. The results are also in good agree-
ment with our findings on the stability of tRNA/mir-34a
chimera in human cells (unpublished data), i.e. the increases
in target small RNAs levels were associated with higher
levels of OnRS chimeras lasting as long as 4 days post-
treatment, which highlights a favorable stability of OnRS
chimeras within human cells. On the other hand, there were
no or diminutive changes in the levels of other cellular miR-
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NAs, and the tRNA-derived tRFs exhibited similar patterns
in the same human cell lines (Figure 2c and d). Nevertheless,
the levels of individual or total tRFs identified in ES-2/GFP
cells were much lower than A549 cells, which is presumably
due to the differences in generating, degrading, excreting
and/or retaining tRFs in different types of cells. In addition,
while the target miRNAs/siRNAs, tRFs and other small
RNAs derived from chimeric ncRNA agents in human cells
were fully elucidated (Supplementary Tables S2 and S4), the
roles of specific ribonucleases such as Dicer in the processes
remain undefined.
The bioactivities of miRNAs (Figure 3) and siRNAs
(Figure 4) released from the OnRS cargo are clearly demon-
strated by the selective suppression of corresponding target
gene expression in vitro and in vivo, using the OnRS/Neg
as a critical control. The transcription factor STAT3, a
known miR-124 target gene (27,28), plays an important
role in many cellular processes such as cell proliferation
and apoptosis. Reduction of STAT3 protein expression lev-
els by miR-124 may at least partially provide an explana-
tion for the enhanced apoptosis and repressed proliferation
of A549 cells (Figure 3). On the other hand, the suppres-
sion of GFP mRNA expression levels in GFP-expressing
ES-2/GFP cells and GFP-transgenic mouse liver tissues by
OnRS-delivered GFP siRNA explains the lower GFP flu-
orescent intensities (Figure 4). While the advantages and
disadvantages of using recombinant DNA agents, synthetic
and recombinant RNAs to achieve RNAi are undoubtedly
subjects of debate, the OnRS-based technology offers a new
opportunity to readily and cost-effectively produce multi-
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milligrams of chimeric miRNA and siRNA agents in a re-
search laboratory setting and allows one to utilize biolog-
ical RNAs to perform RNA actions in vitro and in vivo.
Nevertheless, the relative selectivity, efficiency and safety of
OnRS-carried RNAi agents, as compared to existing agents
or methods, await more extensive evaluation.
The utility of OnRS was further extended to consistent
high-yield production of RNA aptamers. A priori it is un-
known whether aptamer activity would still be present in
the tRNA (13–15) and 5S rRNA (16) scaffolds, although ri-
bozyme activity was observed in the context of the tRNA
scaffold when Hammerhead ribozyme sequences were in-
serted together with the target RNA to be produced (15).
The OnRS-resembled RNA aptamer MGA sensor indeed
interacted with MG to produce a specific strong fluores-
cence at 630/650 nm (excitation/emission; Figure 5e), as it
was originally discovered (9), which was further employed
for the determination of serum RNase activities in clinical
samples (Figure 6e). The RNase activity assay using label-
free MGA sensor developed in this study is different from
current methods. The Kunitz RNase activity assay (29,34–
36) is based upon the ultraviolet absorbance of label-free nu-
cleic acids at 260 nm or nucleosides at 280 nm, which is rela-
tively less selective and sensitive. Recent and current RNase
activity assays including those commercially-available kits
rely on isotope- or fluorophore-labeled RNAs or antibod-
ies (37–40), and thus offer greater sensitivities to determine
very low levels of RNase activities or indicate RNase pro-
tein levels. However, human serum is comprised of much
higher RNase activities. Without extensive dilutions (e.g.
1:1000) of the serum sample that might affect the RNase
activity assay including linear range, larger quantities (e.g.
>10 g) of labeled synthetic RNA agents are needed, and
thus the assays become costly. After careful examination of
the linearity in relation to MG and OnRS/MGA concen-
trations as well as the quantity of human serum and incu-
bation time, we were able to establish a fluorescence-based
RNase assay using label-free OnRS/MGA sensor. Consis-
tent with previous findings (29,36,38), our assays revealed
a significantly higher serum RNase activity in PDAC pa-
tients which may be attributable to the major form RNase
A released from the cancerous pancreases.
In summary, we presented a novel OnRS-based general
approach for a consistent high-yield production of chimeric
RNAs in commonE. coli strains that carry functional small
RNAs of interests such as miRNAs, siRNAs and RNA ap-
tamers. This approach is proven robust and versatile and
shall have broad applications to engineer chimeric ncRNAs,
which may be utilized as in vitro and in vivo research tools
and further developed as diagnostic and therapeutic agents.
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